Dompé U.S. Pays $32 Million to Resolve Co-Pay Foundation Kickback Allegations Following Voluntary Self-Disclosure September 15, 2026 By Abdie Santiago & Jeffrey N. Wasserstein & Anne K. Walsh —

https://www.thefdalawblog.com/2026/09/dompe-u-s-pays-32-million-to-resolve-co-pay-foundation-kickback-allegations-following-voluntary-self-disclosure/?utm_source=rss&utm_medium=rss&utm_campaign=dompe-u-s-pays-32-million-to-resolve-co-pay-foundation-kickback-allegations-following-voluntary-self-disclosure On September 10, 2026, the U.S. Attorney’s Office for the District of Massachusetts announced that Dompé U.S., Inc. agreed to pay $32 million to resolve allegations that it used patient assistance foundations to cover Medicare co-pays for patients receiving Oxervate, a biologic used to treat neurotrophic keratitis, a rare degenerative disease of the cornea. The settlement is the latest in a long line of government actions examining manufacturer support for patient assistance programs that subsidize Medicare beneficiaries’ out-of-pocket costs through independent charitable foundations. The publicly available settlement agreement contains a considerable amount of detail and provides useful insight into both the conduct at issue and the steps that earned the company cooperation credit.